Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 7/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.45 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839401 | 0.91 | KMT2A (0.51) | PARP1PARP2PARP3KDM4EALDH1A1 | |
| SCHEMBL4844426 | 0.88 | PARP1 (0.56) | PARP1PARP2PARP3KDM4EALDH1A1 | |
| SCHEMBL4850567 | 0.87 | PARP1 (0.57) | PARP1PARP2PARP3KDM4EALDH1A1 | |
| SCHEMBL4841013 | 0.85 | PARP1 (0.58) | GRM2PARP1PARP2PARP3KDM4E | |
| SCHEMBL28844223 | 0.80 | PARP1 (0.49) | GRM2PARP1CHRM3CXCR4PARP2 | |
| SCHEMBL4848465 | 0.78 | CXCR4 (0.48) | CXCR4MEN1KMT2AHTR6SIGMAR1 | |
| SCHEMBL20567143 | 0.76 | CHRM3 (0.51) | GRM2PARP1CHRM3CXCR4PARP2 | |
| SCHEMBL30799020 | 0.76 | SLC6A4 (0.58) | CHRM3SIGMAR1 | |
| SCHEMBL4176561 | 0.76 | SLC6A4 (0.58) | CHRM3SIGMAR1 | |
| SCHEMBL4847358 | 0.75 | KDM4E (0.57) | PARP1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368462-B1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080058423-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058423-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC4R | GRM2 551/4885PARP1 4873/4885CHRM3 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.